Skip to main content
. 2018 Jul 18;11(7):1210–1216. doi: 10.18240/ijo.2018.07.22

Table 1. Descriptive analysis of sociodemographic variables and variables of interest pre-phacoemulsification.

Clinical characteristic Total Bromfenac 0.09% Nepafenac 0.1% Diclofenac sodium 0.1% P
Sex, n (%)
 M 103 (42.4) 38 (47.5) 29 (37.2) 36 (42.4) 0.423
 F 140 (57.6) 42 (52.5) 49 (62.8) 49 (57.6)
Age 71.7±9.3 74.2±9.3 70.1±8.4 70.7±9.8 0.012
Nationality, n (%)
 Spanish 221 (90.9) 77 (96.3) 68 (87.2) 76 (89.4) 0.115
 Foreign 22 (9.1) 3 (3.8) 10 (12.8) 9 (10.6)
Eye, n (%)
 Right 123 (51.0) 34 (42.5) 39 (51.3) 50 (58.8) 0.111
 Left 118 (49.0) 46 (57.5) 37 (48.7) 35 (41.2)
Diabetes mellitus, n (%)
 No 169 (69.5) 56 (70.0) 54 (69.2) 59 (69.4) 0.994
 Yes 74 (30.5) 24 (30.0) 24 (30.8) 26 (30.6)
Anaesthetic, n (%)
 Topical 146 (60.8) 50 (62.5) 52 (68.4) 44 (52.4) 0.108
 Local 94 (39.2) 30 (37.5) 24 (31.6) 40 (47.6)
Pre-S average thickness 269.7±28.2 267.0±34.9 272.5±24.7 269.6±24.1 0.481
Pre-S center thickness 243.9±64.3 243.3±77.6 256.4±52.2 233.3±59.1 0.073
Pre-S total volume 7.63±0.80 7.56±0.98 7.70±0.70 7.62±0.68 0.507
Visual acuity (basal) 0.43±0.24 0.42±0.25 0.41±0.25 0.45±0.22 0.416
IOP (basal) 19.21±6.65 18.81±6.42 19.20±5.19 19.60±7.95 0.751

Pre-S: Pre-surgery; IOP: Intraocular pressure. Patients treated with bromfenac 0.09%, nepafenac 0.1% and diclofenac sodium 0.1% eye drops.